On April 10, 2025, the U.S. Food and Drug Administration (FDA) unveiled a landmark plan to phase out the animal testing requirement for monoclonal antibodies and other drugs. This is huge news for companies working at the cutting edge of new approach methodologies (NAMs) — including human organoids and organ-on-chip systems — and marks a bold shift toward more human-relevant, efficient, and ethical drug development. (fda.gov)
As a company fully committed to automating organoid testing in drug discovery, this change isn’t just relevant—it’s transformational. Here’s why, what it means, and how our work aligns with the FDA’s direction.
What Did the FDA Announce?
- The FDA is reducing or replacing traditional animal-testing requirements with alternatives: computational models, in vitro human cell and organoid systems, organ-on-chip platforms, and use of real-world human safety data.
- Starting immediately, in investigational new drug (IND) applications, inclusion of NAMs data (including human organoid toxicity testing) is officially encouraged.
- A roadmap has been released, along with plans for workshops and a pilot program allowing developers to use non-animal strategies under FDA consultation.
Why This Matters — Especially to Organoid Innovation
- Validation of Organoid Models
The FDA’s plan confirms what we already know: organoids can capture human biology in ways animals cannot. - Faster and More Efficient Development
By reducing reliance on animal models, companies can save time and cost while generating data that’s more predictive of human outcomes. - Competitive Advantage
Automated, reproducible organoid testing isn’t just science — it’s now a regulatory priority, positioning organoid innovators at the forefront of drug discovery. - Ethical Progress
Phasing out animal testing reflects a shift toward humane science that aligns with broader public, investor, and ESG expectations.
What This Means for Our Work
For us, this FDA announcement is both validation and motivation. It reinforces the importance of the work we’re already doing — building automated organoid testing systems designed for scalability and reproducibility. By streamlining workflows and reducing variability, we’re creating tools that can deliver the kind of consistent, human-relevant data regulators are asking for.
It also pushes us to deepen our role as partners in this shift. We will continue refining our systems, ensuring they meet the high bar of regulatory standards, while engaging with industry and scientific communities to help shape best practices.
Most importantly, this change highlights that organoid testing is no longer a “next-generation” idea — it’s becoming central to how drugs will be developed. That future is arriving faster than many expected, and we’re proud to be building the automation and infrastructure that will help make it possible.
Conclusion
The FDA’s announcement is more than regulatory policy—it marks a cultural and scientific turning point. For organoid companies that are automating, refining, and validating human-based models, this is an inflection moment. If we align properly, we can help drive safer, faster, more ethical drug development—and be central to the next generation of translational science.
